ALRS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ALRS is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has a mildly bullish technical setup, but the overall picture is mixed: no recent news catalyst, no strong proprietary buy signal, neutral hedge fund and insider activity, and analyst sentiment is only Neutral/Market Perform despite modestly higher price targets. I would not call it a clear buy today; a hold is the better call.
Trend is moderately bullish. The stock is trading at 26.91, slightly below the first resistance at 27.357 and above pivot support at 26.302. MACD histogram is positive at 0.0955, but it is contracting, which suggests momentum is still positive but fading. RSI_6 at 66.559 is near overbought territory but not extreme. The moving averages are bullish with SMA_5 > SMA_20 > SMA_200, confirming an upward trend. However, the stock is close to short-term resistance and the candlestick-based outlook is only mixed, with roughly flat performance expected over the next month.
supports the existing uptrend.", "Positive MACD histogram shows momentum is still upward, even if it is slowing.", "Q1 results were strong on profitability, with net income up 73.81% YoY and EPS up 71.15% YoY.", "Analysts raised price targets on 2026-05-01, which signals improving expectations.", "Options positioning is heavily call-skewed, suggesting bullish sentiment."]
["No recent news in the past week, so there is no fresh event-driven catalyst.", "Revenue fell 32.69% YoY in the latest quarter, which is a meaningful top-line weakness.", "MACD histogram is positive but contracting, hinting that the rally may be losing strength.", "RSI is near overbought levels, making the stock less attractive for an immediate new entry.", "AI Stock Picker and SwingMax both show no signal today or recently.", "Insiders and hedge funds are neutral, and there is no recent congress or influential figure trading data."]
In Q1 2026, ALRS showed a mixed earnings profile. Revenue declined to 45.94 million, down 32.69% YoY, which is the main weakness. However, profitability improved sharply: net income rose 73.81% YoY to 22.97 million and EPS increased 71.15% YoY to 0.89. This indicates better margin and expense control, but the revenue decline makes the quarter less compelling as a durable growth story.
Recent analyst trend is mildly constructive but still cautious. On 2026-05-01, Keefe Bruyette raised its price target to 27 from 25 and kept a Market Perform rating. Piper Sandler raised its target to 28.50 from 28 and kept a Neutral rating, citing strong Q1 performance with 19% PPNR upside driven by stronger net interest income, margin expansion, and controlled operating expenses. Overall, Wall Street is neutral rather than bullish: the pros acknowledge improving earnings quality, but the stock is still not rated as an outperform.
